Clinical Trial Update: A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio [Phase 2]

View source ↗

Summary

Phase 2 randomized, placebo-controlled trial evaluating multidose APL-3007 in combination with pegylated complement inhibitor Syfovre (pegcetacoplan) for geogra…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Geographic Atrophy Secondary to Age-related Macular Degeneration

Drugs mentioned

• APL-3007 Multidose
• Syfovre (pegcetacoplan) (pegcetacoplan)

Snippet

Sponsor: Apellis Pharmaceuticals, Inc. | Conditions: Geographic Atrophy Secondary to Age-related Macular Degeneration | Phase 2 | Status: RECRUITING